CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases

Kidney International

Volumn 73, Issue 6, 2008, Pages 684-690

  Obligado, S H ^a   Ibraghimov Beskrovnaya, O ^b   Zuk, A ^b   Meijer, L ^c,d   Nelson, P J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENZYME CORPORATION   (United States)

^c CNRS   (France)

^d ManRos Therapeutics   (France)

Author keywords

Apoptosis; Chronic kidney disease; End stage renal disease; Immunology; Proliferation

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 6 BROMOINDIRUBIN 3' OXIME; BETA CATENIN; BIOLOGICAL MARKER; CHLORMETHINE; COMPLEMENT; CREATININE; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; FLAVONE DERIVATIVE; FLAVOPIRIDOL; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; IMATINIB; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INDIRUBIN; INDOLE DERIVATIVE; LITHIUM; MALEIMIDE DERIVATIVE; OLOMOUCINE; PROTEIN; PROTEIN SERINE THREONINE KINASE; PURINE DERIVATIVE; PURVALANOL B; ROSCOVITINE; STEROID; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GLOMERULOPATHY; HUMAN; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SHORT SURVEY;

EID: 40049091449     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002731     Document Type: Short Survey

References (86)

1. H. Chasis W. Goldring D.S. Baldwin The effect of nitrogen mustard on renal manifestations of human glomerulonephritis J Clin Invest 29 1950 804
2. J.A. Luetscher Jr Q.B. Deming Treatment of nephrosis with cortisone J Clin Invest 29 1950 1576 1587
3. M.W. Moncrieff R.H. White C.S. Oggs J.S. Cameron Cyclophosphamide therapy in the nephrotic syndrome in childhood BMJ 1 1969 666 671
4. E.C. Butcher E.L. Berg E.J. Kunkel Systems biology in drug discovery Nat Biotechnol 22 2004 1253 1259
5. T. Wada J.W. Pippin C.B. Marshall Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins J Am Soc Nephrol 16 2005 2615 2625
6. C.Y. Xing M.A. Saleem R.J. Coward Direct effects of dexamethasone on human podocytes Kidney Int 70 2006 1038 1045
7. M. Malumbres M. Barbacid Mammalian cyclin-dependent kinases Trends Biochem Sci 30 2005 630 641
8. M. Knockaert P. Greengard L. Meijer Pharmacological inhibitors of cyclin-dependent kinases Trends Pharmacol Sci 23 2002 417 425
9. R.S. Jope G.V. Johnson The glamour and gloom of glycogen synthase kinase-3 Trends Biochem Sci 29 2004 95 102
10. P. Cohen M. Goedert GSK3 inhibitors: development and therapeutic potential Nat Rev Drug Discov 3 2004 479 487
11. L. Meijer M. Flajolet P. Greengard Pharmacological inhibitors of glycogen synthase kinase 3 Trends Pharmacol Sci 25 2004 471 480
12. S. Frame D. Zheleva Targeting glycogen synthase kinase-3 in insulin signalling Expert Opin Ther Targets 10 2006 429 444
13. L. Dugo M. Collin C. Thiemermann Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation Shock 27 2007 113 123
14. P. Romagnani L. Lasagni B. Mazzinghi Pharmacological modulation of stem cell function Curr Med Chem 14 2007 1129 1139
15. P.J. Nelson S.J. Shankland Therapeutics in renal disease: the road ahead for antiproliferative targets Nephron Exp Nephrol 103 2006 e6 e15
16. T.J. Soos L. Meijer P.J. Nelson CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases Drug News Perspect 19 2006 325 328
17. G. Manning D.B. Whyte R. Martinez The protein kinase complement of the human genome Science 298 2002 1912 1934
18. S. Caenepeel G. Charydczak S. Sudarsanam The mouse kinome: discovery and comparative genomics of all mouse protein kinases Proc Natl Acad Sci USA 101 2004 11707 11712
19. S. Bach M. Bondel L. Meijer Evaluation of CDK Inhibitors' Selectivity: from Affinity Chromatography to Yeast Genetics vol. 5 2006 CRC Press, Taylor & Francis 103 119
20. D. Guiffant D. Tribouillard F. Gug Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography Biotechnol J 2 2007 68 75
21. L. Meijer A.M. Thunnissen A.W. White Inhibition of cyclin-dependent kinases GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent Chem Biol 7 2000 51 63
22. S. Leclerc M. Garnier R. Hoessel Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 276 2001 251 260
23. L. Meijer A.L. Skaltsounis P. Magiatis GSK-3-selective inhibitors derived from Tyrian purple indirubins Chem Biol 10 2003 1255 1266
24. S. Bach M. Knockaert J. Reinhardt Roscovitine targets, protein kinases and pyridoxal kinase J Biol Chem 280 2005 31208 31219
25. P.M. Fischer CDK versus GSK-3 inhibition: a purple haze no longer? Chem Biol 10 2003 1144 1146
26. J.H. Lin A.Y. Lu Role of pharmacokinetics and metabolism in drug discovery and development Pharmacol Rev 49 1997 403 449
27. R. Frank R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 2003 566 580
28. P. Polychronopoulos P. Magiatis A.L. Skaltsounis Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases J Med Chem 47 2004 935 946
29. S.H. Chao K. Fujinaga J.E. Marion Flavopiridol inhibits P-TEFb and blocks HIV-1 replication J Biol Chem 275 2000 28345 28348
30. J. Vesely L. Havlicek M. Strnad Inhibition of cyclin-dependent kinases by purine analogues Eur J Biochem 224 1994 771 786
31. N.S. Gray L. Wodicka A.M. Thunnissen Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 281 1998 533 538
32. F.I. Raynaud S.R. Whittaker P.M. Fischer In vitro and in vivo pharmacokinetic–pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202 Clin Cancer Res 11 2005 4875 4887
33. M.P. Coghlan A.A. Culbert D.A. Cross Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription Chem Biol 7 2000 793 803
34. A. Martinez M. Alonso A. Castro First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease J Med Chem 45 2002 1292 1299
35. J.W. Pippin Q. Qu L. Meijer S.J. Shankland Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist J Clin Invest 100 1997 2512 2520
36. C. Zoja F. Casiraghi S. Conti Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus Arthritis Rheum 56 2007 1629 1637
37. S.V. Griffin R.D. Krofft J.W. Pippin S.J. Shankland Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis Kidney Int 67 2005 977 986
38. P.J. Nelson I.H. Gelman P.E. Klotman Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes J Am Soc Nephrol 12 2001 2827 2831
39. P.J. Nelson M. Sunamoto M. Husain I.H. Gelman HIV-1 expression induces cyclin D1 expression and pRb phosphorylation in infected podocytes: cell-cycle mechanisms contributing to the proliferative phenotype in HIV-associated nephropathy BMC Microbiol 2 2002 26
40. P.J. Nelson V.D. D'Agati J.M. Gries Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol J Antimicrob Chemother 51 2003 921 929
41. D. Gherardi V. D'Agati T.H. Chu Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202 J Am Soc Nephrol 15 2004 1212 1222
42. N.O. Bukanov L.A. Smith K.W. Klinger Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine Nature 444 2006 949 952
43. C.L. Lin J.Y. Wang Y.T. Huang Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells J Am Soc Nephrol 17 2006 2812 2820
44. K. Hiromura J.W. Pippin M.J. Blonski The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation Oncogene 21 2002 1750 1758
45. P.M. Price J. Megyesi R.L. Saf Irstein Cell cycle regulation: repair and regeneration in acute renal failure Kidney Int 66 2004 509 514
46. P.M. Price R.L. Safirstein J. Megyesi Protection of renal cells from cisplatin toxicity by cell cycle inhibitors Am J Physiol Renal Physiol 286 2004 F378 F384
47. P.M. Price F. Yu P. Kaldis Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2 J Am Soc Nephrol 17 2006 2434 2442
48. F. Yu J. Megyesi R.L. Safirstein P.M. Price The involvement of the Cdk2-E2f1 pathway in cisplatin cytotoxicity in vitro and in vivo Am J Physiol Renal Physiol 293 2007 F52 F59
49. A. Benigni C. Caroli L. Longaretti Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus Arthritis Rheum 56 2007 1569 1578
50. R. Gong A. Rifai L.D. Dworkin Activation of PI3K-Akt-GSK3beta pathway mediates hepatocyte growth factor inhibition of RANTES expression in renal tubular epithelial cells Biochem Biophys Res Commun 330 2005 27 33
51. R. Gong A. Rifai L.D. Dworkin Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium J Am Soc Nephrol 17 2006 2464 2473
52. R. Gong A. Rifai L.D. Dworkin Hepatocyte growth factor suppresses acute renal inflammation by inhibition of endothelial E-selectin Kidney Int 69 2006 1166 1174
53. M. Martin K. Rehani R.S. Jope S.M. Michalek Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3 Nat Immunol 6 2005 777 784
54. E. Rodionova M. Conzelmann E. Maraskovsky GSK-3 mediates differentiation and activation of pro-inflammatory dendritic cells Blood 109 2007 1584 1592
55. A.G. Rossi D.A. Sawatzky A. Walker Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis Nat Med 12 2006 1056 1064
56. S. Kuure A. Popsueva M. Jakobson Glycogen synthase kinase-3 inactivation and stabilization of beta-catenin induce nephron differentiation in isolated mouse and rat kidney mesenchymes J Am Soc Nephrol 18 2007 1130 1139
57. D. Sinha Z. Wang K.L. Ruchalski Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors Am J Physiol Renal Physiol 288 2005 F703 F713
58. V.R. Price C.A. Reed W. Lieberthal J.H. Schwartz ATP depletion of tubular cells causes dissociation of the zonula adherens and nuclear translocation of beta-catenin and LEF-1 J Am Soc Nephrol 13 2002 1152 1161
59. Y. Terada H. Tanaka T. Okado Expression and function of the developmental gene Wnt-4 during experimental acute renal failure in rats J Am Soc Nephrol 14 2003 1223 1233
60. M.H. Little Regrow or repair: potential regenerative therapies for the kidney J Am Soc Nephrol 17 2006 2390 2401
61. L.G. Cantley Adult stem cells in the repair of the injured renal tubule Nat Clin Pract Nephrol 1 2005 22 32
62. J.S. Duffield K.M. Park L.L. Hsiao Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells J Clin Invest 115 2005 1743 1755
63. F. Lin A. Moran P. Igarashi Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney J Clin Invest 115 2005 1756 1764
64. F. Togel Z. Hu K. Weiss Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms Am J Physiol Renal Physiol 289 2005 F31 F42
65. E.I. Prodromidi R. Poulsom R. Jeffery Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome Stem Cells 24 2006 2448 2455
66. H. Sugimoto T.M. Mundel M. Sund Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease Proc Natl Acad Sci USA 103 2006 7321 7326
67. Q. Al-Awqati J.A. Oliver The kidney papilla is a stem cells niche Stem Cell Rev 2 2006 181 184
68. C. Sagrinati G.S. Netti B. Mazzinghi Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys J Am Soc Nephrol 17 2006 2443 2456
69. N. Sato L. Meijer L. Skaltsounis Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor Nat Med 10 2004 55 63
70. J.J. Trowbridge A. Xenocostas R.T. Moon M. Bhatia Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation Nat Med 12 2006 89 98
71. M. Milovanceva-Popovska U. Kunter T. Ostendorf R -roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury Kidney Int 67 2005 1362 1370
72. O. Ibraghimov-Beskrovnaya Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy Cell Cycle 6 2007 776 779
73. J. Megyesi L. Andrade J.M. Vieira Jr Positive effect of the induction of p21WAF1/CIP1 on the course of ischemic acute renal failure Kidney Int 60 2001 2164 2172
74. G. Duyk Attrition and translation Science 302 2003 603 605
75. J.M. Reichert Trends in development and approval times for new therapeutics in the United States Nat Rev Drug Discov 2 2003 695 702
76. J.F. Pritchard M. Jurima-Romet M.L. Reimer Making better drugs: decision gates in non-clinical drug development Nat Rev Drug Discov 2 2003 542 553
77. W.M. Bennett Off-label use of approved drugs: therapeutic opportunity and challenges J Am Soc Nephrol 15 2004 830 831
78. J. Wagner Potential role of retinoids in the therapy of renal disease Nephrol Dial Transplant 16 2001 441 444
79. V.M. Campese J. Park HMG-CoA reductase inhibitors and the kidney Kidney Int 71 2007 1215 1222
80. P. Iglesias J.J. Diez Peroxisome proliferator-activated receptor gamma agonists in renal disease Eur J Endocrinol 154 2006 613 621
81. P. Greaves A. Williams M. Eve First dose of potential new medicines to humans: how animals help Nat Rev Drug Discov 3 2004 226 236
82. M.G. Janech J.R. Raymond J.M. Arthur Proteomics in renal research Am J Physiol Renal Physiol 292 2007 F501 F512
83. T. Pisitkun R. Johnstone M.A. Knepper Discovery of urinary biomarkers Mol Cell Proteomics 5 2006 1760 1771
84. J.J. Grantham V.E. Torres A.B. Chapman Volume progression in polycystic kidney disease N Engl J Med 354 2006 2122 2130
85. R. Perrone Imaging progression in polycystic kidney disease N Engl J Med 354 2006 2181 2183
86. A. Villar-Garea M. Griese A. Imhof Biomarker discovery from body fluids using mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 849 2007 105 114